GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » EBIT

BioSig Technologies (BioSig Technologies) EBIT : $-28.51 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies EBIT?

BioSig Technologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-6.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-28.51 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioSig Technologies's annualized ROC % for the quarter that ended in Dec. 2023 was -1,208.92%. BioSig Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,393.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioSig Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -186.72%.


BioSig Technologies EBIT Historical Data

The historical data trend for BioSig Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies EBIT Chart

BioSig Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.60 -59.18 -33.41 -27.27 -28.51

BioSig Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.00 -7.39 -10.91 -4.05 -6.17

Competitive Comparison of BioSig Technologies's EBIT

For the Medical Devices subindustry, BioSig Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's EV-to-EBIT falls into.



BioSig Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSig Technologies  (NAS:BSGM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioSig Technologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-24.668 * ( 1 - 0% )/( (2.446 + 1.635)/ 2 )
=-24.668/2.0405
=-1,208.92 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioSig Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.668/( ( (1.123 + max(-3.012, 0)) + (0.938 + max(-3.998, 0)) )/ 2 )
=-24.668/( ( 1.123 + 0.938 )/ 2 )
=-24.668/1.0305
=-2,393.79 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.014 + 0.219 + 0.327) - (3.568 + 0.004 + 0)
=-3.012

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.024 + 0 + 0.211) - (4.217 + 0.016 + 0)
=-3.998

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioSig Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-28.512/15.270
=-186.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSig Technologies EBIT Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies (BioSig Technologies) Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial stage medical device company. It is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044